ROUMEN TSANEV INSTITUTE OF MOLECULAR BIOLOGY BULGARIAN ACADEMY OF SCIENCES

Their core work

IMB-BAS is a fundamental research institute within the Bulgarian Academy of Sciences, specializing in molecular biology at the cellular and subcellular level. In H2020, they applied this biological expertise to the field of nanomaterial safety — contributing to NanoREG II, a major European effort to build regulatory-ready methodologies for grouping nanomaterials and implementing safe-by-design principles. They also hold a minor stake in the European BioImaging infrastructure network, suggesting access to advanced imaging capabilities relevant to cellular and molecular research. Their value in consortia lies in providing biological assay expertise and molecular-level insights needed to assess how engineered nanomaterials interact with living systems.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2015-2016, making a meaningful early-versus-late evolution difficult to detect — there is essentially no post-2019 H2020 activity recorded for this organization. Their documented focus is anchored firmly in nanosafety regulation and nanomaterial grouping methodologies, as captured in NanoREG II keywords. The EuBI PPII project carried no recorded keywords and contributed negligible funding, so it reveals little about a strategic shift. Based on available data, no clear directional change in focus can be confirmed; the nanosafety-regulation theme is the only substantiated track.

With no H2020 activity recorded after 2016 and only two projects in narrow timeframes, the institute's trajectory beyond nanosafety regulation is unclear — a prospective partner should verify current research priorities directly with IMB-BAS before assuming continued engagement in this domain.

How they like to work

IMB-BAS has participated exclusively as a consortium partner in both H2020 projects, never taking on a coordinating role. They operate within large, multi-national consortia — NanoREG II alone likely involved dozens of partners given the 61 unique collaborators across 20 countries recorded for just two projects. This pattern suggests they function best as a specialist contributor within established research networks rather than as an organizational lead.

Despite only two projects, IMB-BAS has connected with 61 unique consortium partners across 20 countries — a strong indicator that NanoREG II was a large, pan-European research initiative with broad participation. Their network is European in reach, though their home base and institutional context are firmly Bulgarian.

What sets them apart

IMB-BAS occupies a specific niche as a Bulgarian molecular biology institute with documented experience in European nanosafety regulation science — a combination that is relatively rare in Southeast Europe. For consortium builders working on nanomaterial risk assessment, safe-by-design frameworks, or regulatory tool development, they offer both the scientific grounding and the EU project track record needed to qualify as a credible partner. Their link to the Euro-BioImaging network also suggests access to shared research infrastructure that smaller partners in a consortium may find valuable.

Highlights from their portfolio

• NanoREG II
  The institute's flagship H2020 engagement — a 4-year RIA project running 2015-2019 with EUR 297,050 in EC funding, focused on building regulatory-ready grouping and safe-by-design tools for nanomaterials across European industry.
• EuBI PPII
  Participation in the Euro-BioImaging Preparatory Phase II connects IMB-BAS to one of Europe's major research infrastructure initiatives, though the symbolic EUR 1,500 in funding signals a peripheral rather than central role.